Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия vvb56@yandex.ru
Список исп. литературыСкрыть список 1. Wu ZS, Zhang ZQ, Wu S. Focus on the Crosstalk Between COVID-19 and Urogenital Systems. J Urol 2020. Apr 3. DOI: 10.1097/JU.0000000000001068 2. Peng L, Liu J, Xu W et al. SARS-CoV-2 Can Be Detected in Urine, Blood, Anal Swabs, and Oropharyngeal Swabs Specimens. J Med Virol 2020. Apr 24. DOI: 10.1002/jmv.25936 3. Guan WJ, Ni ZY, Hu Yet al; China Medical Treatment Expert Group for Covid-19. Clinical characteristics of 2019 novel coronavirus infection in China. N Engl J Med 2020; 382 (18): 1708–20. DOI: 10.1056/NEJMoa2002032 4. Sun J, Zhu A, Li H et al. Isolation of Infectious SARS-CoV-2 from Urine of a COVID-19 Patient. Emerg Microbes Infect 2020; 28: 1–8. DOI: 10.1080/22221751.2020.1760144 5. Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in Different Types of Clinical Specimens. JAMA 2020; 323 (18): 1843–4. DOI: 10.1001/ jama.2020.3786 6. Вишневский Е.Л., Пушкарь Д.Ю., Лоран О.Б. и др. Урофлоуметрия. М.: Печатный Город, 2004. [Vishnevskii E.L., Pushkar' D.Iu., Loran O.B. et al. Urofloumetriia. M.: Pechatnyi Gorod, 2004 (in Russian).] 7. Andrew J, Nathan PW. Lesions of the anterior frontal lobes and disturbances of micturition and defecation. Brain 1964; 87: 233–62. 8. Griffiths, Derek J. Use of functional imaging to monitor central control of voiding in humans. Urinary Tract. Springer, Berlin, Heidelberg, 2011. P. 81-97 9. Григорашвили И.И. Значение дисфункции вегетативной нервной системы при идиопатическом гиперактивном мочевом пузыре у женщин. Дис. … канд. мед. наук. М., 2009. [Vishnevskii E.L., Pushkar' D.Iu., Loran O.B. et al. Urofloumetriia. Moscow: Pechatnyi Gorod, 2004 (in Russian).] 10. Burkhard F.C. (Chair) et al. EAU Guidelines on Urinary Incontinence, 2016. 11. Napier & Gupta Darifenacin is selective for the human recombinant M3 receptor subtype. Neurourol Urodyn 2002; 21: A445. 12. Doroshyenko et al. Clinical pharmacokinetics of trospium chloride. Clin Pharmacokinet 2005; 44 (7): 701–20. 13. Waterbeemd et al Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors. J Drug Target 1998; 6: 151–5. 14. Kessler TM et al. Adverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approach. PLoS One 2011; 6 (2): e16718. 15. Staskin D, Kay G, Tannenbaum C et al. Trospium chloride has no effect on memory testing and is assay undetectable in the central nervous system of older patients with overactive bladder. Int J Clin Pract 2010; 64 (9): 1294–300. 16. Abrams P et al. Incontinence: 5th International Consultation on Incontinence, Paris, February 2012. 5th Edition. ICUD-EAU, 2013. 17. Pietzko et al. Influences of trospium chloride and oxybutynin on quantitative EEG in healthy volunteers. Eur J Clin Pharmacology 1994; 47: 337–43. 18. Diefienbach K, Maurer A et al. Randomised, double-blind study of the effects of oxybutynin, tolterodine, trospium chloride and placebo on sleep in healthy young volunteers. Clin Drug Investig 2003; 23 (6): 395–404. 19. Herberg KW, Fussgen I: Einfluss von Trospiumchlorid, Oxybutynin-HCl und Propiverin-HCl auf sicherheitsrelevante Leistungen. Geriatrie Forschung 1997; 7 (2): 77–83. 20. Rudy D. Time to onset of improvement in symptoms of overactive bladder using antimuscarinic treatment. BJU International 2006; 97: 540–46.